The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Agendia; Amgen; Aristo; AstraZeneca; Boehringer Ingelheim; Carl Zeiss Meditec; Celgene; ClinSol; Daiichi Sankyo; Eisai; Genomic Health; GlaxoSmithKline; Hexal; Lilly; Medstrom Medical; MSD; Mundipharma; NanoString Technologies; Novartis; Odonate Therapeutics; Onkowissen; Palleos; Paxman
Speakers' Bureau - Agendia; Amgen; Aristo; AstraZeneca; Boehringer Ingelheim; Celgene; ClinSol; Daiichi Sankyo; Eisai; Genomic Health; GlaxoSmithKline; Hexal; Lilly; Medstrom Medical; MSD; Mundipharma; NanoString Technologies; Novartis; Odonate Therapeutics; Onkowissen; Palleos; Paxman; ZEISS
Travel, Accommodations, Expenses - Agendia; Amgen; Aristo; AstraZeneca; Boehringer Ingelheim; Carl Zeiss Meditec; Celgene; ClinSol; Daiichi Sankyo; Eisai; Genomic Health; GlaxoSmithKline; Hexal; Lilly; Medstrom Medical; MSD; Mundipharma; NanoString Technologies; Novartis; Odonate Therapeutics; Onkowissen; Palleos; Paxman
De-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel weekly in HR-/HER2+ early breast cancer: ADAPT-HR-/HER2+ biomarker and survival results.
 
Nadia Harbeck
Stock and Other Ownership Interests - West German Study Group
Honoraria - Amgen; AstraZeneca; Genomic Health; Novartis; Pfizer; Pierre Fabre; Roche; Zodiac Pharma
Consulting or Advisory Role - Agendia; AstraZeneca; Celgene; Daiichi Sankyo; Lilly; Merck Sharp & Dohme; Novartis; Odonate Therapeutics; Pfizer; Pierre Fabre; Roche/Genentech; Sandoz; Seagen; West German Study Group (I)
Research Funding - Lilly (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Oleg Gluz
Honoraria - AstraZeneca; Celgene; Genomic Health/Exact Sciences; NanoString Technologies; Novartis; Pfizer; Roche
Consulting or Advisory Role - Celgene; Genomic Health/Exact Sciences; Lilly; MSD; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Roche
Other Relationship - West German Study Group
 
Matthias Christgen
Other Relationship - West German Study Group
 
Sherko Kuemmel
Consulting or Advisory Role - Amgen; AstraZeneca; Celgene; Daiichi Sankyo; Genomic Health; Lilly; MSD Oncology; Novartis; Pfizer; pfm medical; Roche/Genentech; SOMATEX; Sonoscape
Travel, Accommodations, Expenses - Daiichi Sankyo; Roche; Sonoscape
(OPTIONAL) Uncompensated Relationships - West German Study Group
 
Eva-Maria Grischke
No Relationships to Disclose
 
Michael Braun
No Relationships to Disclose
 
Jochem Potenberg
No Relationships to Disclose
 
Katja Krauss
Stock and Other Ownership Interests - Fresenius (I)
Honoraria - Celgene; MSD; Pfizer; Reuter Medico Consulting; RG Gesellschaft für Information und Organisation mbH; Roche
Research Funding - Novartis
 
Claudia Schumacher
No Relationships to Disclose
 
Helmut Forstbauer
No Relationships to Disclose
 
Toralf Reimer
Consulting or Advisory Role - Pfizer
Research Funding - Else Kröner-Fresenius-Stiftung; German Cancer Aid
Other Relationship - Pfizer
 
Andrea Stefek
No Relationships to Disclose
 
Hans Holger Fischer
Honoraria - AstraZeneca; Exact Sciences; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Exact Sciences; Pfizer; Roche
Speakers' Bureau - AstraZeneca; Exact Sciences; Pfizer; Roche
 
Enrico Pelz
No Relationships to Disclose
 
Monika Graeser
No Relationships to Disclose
 
Christine zu Eulenburg
No Relationships to Disclose
 
Ronald E. Kates
Honoraria - Amgen (I); AstraZeneca (I); Genomic Health (I); Novartis (I); Pfizer (I); Pierre Fabre (I); Roche (I); Zodiac Pharma (I)
Consulting or Advisory Role - Agendia (I); AstraZeneca (I); Celgene (I); Daiichi Sankyo (I); Lilly (I); Merck Sharp & Dohme (I); Novartis (I); Odonate Therapeutics (I); Pfizer (I); Pierre Fabre (I); Roche/Genentech (I); Sandoz (I); Seagen (I); West German Study Group
Research Funding - Lilly (I); Merck Sharp & Dohme (I); Novartis (I); Pfizer (I); Roche/Genentech (I)
Other Relationship - West German Study Group (I)
 
Rachel Wuerstlein
No Relationships to Disclose
 
Hans Heinrich Kreipe
No Relationships to Disclose
 
Ulrike Nitz
Honoraria - Agendia; Amgen; Celgene; Genomic Health; NanoString Technologies; Novartis; Pfizer; Roche/Genentech; Teva
Consulting or Advisory Role - Genomic Health; Roche
Research Funding - Agendia (Inst); Amgen (Inst); Celgene (Inst); Genomic Health (Inst); NanoString Technologies (Inst); Roche (Inst); Sanofi (Inst)
Expert Testimony - Genomic Health
Travel, Accommodations, Expenses - Genomic Health; Pfizer; Roche
Other Relationship - West German Study Group